Swedish Orphan Biovitrum AB is an international biopharmaceutical company specializing in the development, manufacturing, and marketing of innovative therapies for rare diseases. Its primary focus lie... Swedish Orphan Biovitrum AB is an international biopharmaceutical company specializing in the development, manufacturing, and marketing of innovative therapies for rare diseases. Its primary focus lies in treating complex conditions within hematology, immunology, inflammation, and genetic and metabolic disorders, notably hemophilia and amyotrophic lateral sclerosis. The company’s portfolio includes biologic medicines such as Eftrenonacog Alfa (Alprolix), Pegcetacoplan (ALTUVOCT), and Avatrombopag (Aspaveli/Empaveli), addressing significant unmet medical needs for both adult and pediatric populations. Swedish Orphan Biovitrum AB is recognized for its expertise in protein biochemistry and biologics manufacturing, supporting a growing pipeline through over 150 clinical trials. Its global footprint spans Europe, the Middle East, North America, Russia, and Asia, making it a key partner for industry and research institutions alike. The company plays an essential role in the biopharmaceutical sector by advancing specialty care and contributing to new therapeutic solutions for vulnerable patient populations worldwide.
Pending data availability
Energy Management Data missing for Swedish Orphan Biovitrum
We haven’t collected Energy Management data for Swedish Orphan Biovitrum yet, or the company
hasn’t made it publicly available.